Faron Pharmaceuticals Oy
LSE:FARN
Cash Flow Statement
Cash Flow Statement
Faron Pharmaceuticals Oy
| Dec-2015 | Jun-2016 | Dec-2016 | Jun-2017 | Dec-2017 | Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||||||||||||
| Net Income |
(6)
|
(7)
|
(10)
|
(14)
|
(21)
|
(28)
|
(20)
|
(12)
|
(13)
|
(14)
|
(17)
|
(20)
|
(21)
|
(24)
|
(29)
|
(29)
|
(31)
|
(32)
|
(26)
|
(31)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Stock-Based Compensation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
1
|
1
|
2
|
2
|
1
|
1
|
|
| Other Non-Cash Items |
1
|
1
|
0
|
1
|
2
|
1
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
5
|
7
|
8
|
13
|
|
| Cash Taxes Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
|
| Cash Interest Paid |
0
|
1
|
0
|
(0)
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Change in Working Capital |
(2)
|
(1)
|
0
|
(1)
|
1
|
2
|
(0)
|
(0)
|
1
|
(0)
|
(1)
|
(1)
|
(2)
|
0
|
4
|
3
|
2
|
4
|
(6)
|
(7)
|
|
| Cash from Operating Activities |
(7)
N/A
|
(7)
+4%
|
(9)
-37%
|
(14)
-46%
|
(18)
-34%
|
(25)
-36%
|
(21)
+18%
|
(13)
+39%
|
(12)
+8%
|
(14)
-24%
|
(17)
-23%
|
(20)
-17%
|
(22)
-9%
|
(22)
0%
|
(23)
-3%
|
(24)
-5%
|
(24)
+1%
|
(20)
+15%
|
(23)
-14%
|
(25)
-7%
|
|
| Investing Cash Flow | |||||||||||||||||||||
| Capital Expenditures |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Other Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash from Investing Activities |
(0)
N/A
|
(0)
+63%
|
(0)
-130%
|
(0)
-42%
|
(0)
+25%
|
(0)
-113%
|
(0)
-41%
|
(0)
+38%
|
(0)
+46%
|
(0)
-38%
|
(0)
-3%
|
(0)
-220%
|
(0)
-4%
|
(0)
+48%
|
(0)
-55%
|
(0)
+26%
|
(0)
+57%
|
(0)
-45%
|
(0)
-27%
|
(0)
+10%
|
|
| Financing Cash Flow | |||||||||||||||||||||
| Net Issuance of Common Stock |
18
|
0
|
9
|
16
|
17
|
28
|
17
|
4
|
16
|
25
|
14
|
15
|
26
|
15
|
13
|
21
|
26
|
49
|
32
|
8
|
|
| Net Issuance of Debt |
0
|
0
|
1
|
1
|
0
|
(0)
|
(0)
|
0
|
0
|
(0)
|
0
|
1
|
0
|
10
|
10
|
(0)
|
(1)
|
(3)
|
(0)
|
8
|
|
| Other |
0
|
0
|
(1)
|
(1)
|
(1)
|
(2)
|
(1)
|
(0)
|
(1)
|
(2)
|
0
|
1
|
(0)
|
0
|
(0)
|
(0)
|
(1)
|
(2)
|
(6)
|
(8)
|
|
| Cash from Financing Activities |
18
N/A
|
13
-25%
|
9
-31%
|
15
+61%
|
17
+11%
|
26
+57%
|
16
-40%
|
4
-71%
|
15
+227%
|
23
+57%
|
15
-36%
|
16
+11%
|
26
+56%
|
26
+0%
|
23
-9%
|
21
-12%
|
24
+16%
|
44
+83%
|
26
-41%
|
9
-66%
|
|
| Change in Cash | |||||||||||||||||||||
| Effect of Foreign Exchange Rates |
0
|
0
|
1
|
0
|
(0)
|
0
|
0
|
(0)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
0
|
0
|
(0)
|
|
| Net Change in Cash |
11
N/A
|
7
-39%
|
0
-94%
|
1
+260%
|
(2)
N/A
|
1
N/A
|
(5)
N/A
|
(8)
-58%
|
3
N/A
|
9
+192%
|
(3)
N/A
|
(5)
-58%
|
3
N/A
|
3
+8%
|
0
-95%
|
(4)
N/A
|
(0)
+97%
|
24
N/A
|
3
-89%
|
(16)
N/A
|
|
| Free Cash Flow | |||||||||||||||||||||
| Free Cash Flow |
(7)
N/A
|
(7)
+5%
|
(10)
-38%
|
(14)
-46%
|
(18)
-33%
|
(25)
-36%
|
(21)
+17%
|
(13)
+39%
|
(12)
+8%
|
(14)
-24%
|
(18)
-22%
|
(21)
-18%
|
(23)
-9%
|
(23)
+1%
|
(23)
-4%
|
(24)
-4%
|
(24)
+2%
|
(20)
+15%
|
(23)
-14%
|
(25)
-7%
|
|